Appointment of New Non-Executive Director

1 November 2010

Cyprotex PLC

("Cyprotex" or the "Company")

Appointment of New Non-Executive Director

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces the appointment of Christopher Gurth Clothier as Non-Executive Director, effective as of 1st November 2010. Mr Clothier will serve on the Audit and Remuneration Committees of the Company.

Mr Clothier, aged 31, is currently Investment Director at IPGL Limited, the Company's second largest shareholder, with a holding of 27, 024,465 ordinary shares representing 12.08% of the issued share capital of the Company. Mr Clothier has previously been Investment Director at MMC Ventures, and a consultant with Roland Berger Strategy Consultants GmbH. Mr Clothier received his MChem from New College, University of Oxford, in 2002.

Mr Steve Harris, Non-Executive Chairman of Cyprotex, said: "We are delighted to welcome Chris Clothier to our Board as Non-Executive Director. Chris brings a wealth of knowledge of the Company and will have invaluable strategic input into the business going forward. The Company's three largest shareholders are now represented on the Board, whose interests are fully aligned with those of the rest of our shareholders."

Mr Chris Clothier added: "I am delighted to be joining Cyprotex at such an exciting time for the business. The recent acquisition of US-based Apredica has substantially enhanced the Company's presence in the US, and has accelerated its entry into the fast-growing in vitro toxicology market, both of which represent significant growth opportunities. As a representative of Cyprotex's second-largest shareholder, I am personally committed to helping the Company enhance shareholder value."

There is no further information to disclose in relation to Schedule 2 paragraph g of the AIM Rules for Companies.

Enquiries:

Notes to Editors:

Cyprotex PLC

Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.

www.cyprotex.com

IPGL Ltd

IPGL Limited is a private holding company which focuses on partnering with experienced management teams to build fast-growing businesses in financial services and other sectors. Michael Spencer, the founder and chief executive of ICAP PLC, together with his wife and family trusts, are majority shareholders of the company.

www.ipgl.co.uk